Research programme: intranasal HIV vaccine - NanoBio

Drug Profile

Research programme: intranasal HIV vaccine - NanoBio

Alternative Names: nanoemulsion-based HIV vaccine - NanoBio

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator NanoBio Corporation
  • Developer Duke Human Vaccine Institute; NanoBio Corporation; National Institutes of Health (USA)
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 28 Jul 2016 Preclinical development is ongoing for HIV infections in USA (NanoBio Corporation pipeline, July 2016)
  • 29 Oct 2013 Preclinical trials in HIV infections (prevention) in USA (Intranasal)
  • 29 Oct 2013 NanoBio Corporation receives contract from National Institute of Allergy and Infectious Diseases for intranasal HIV vaccine development in prevention of HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top